LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with raised guidance for revenue growth, EPS, and free cash flow. The Q&A section highlights strategic investments in capacity expansion and new product launches, despite some conservative Q4 guidance. The positive feedback on the Essenz launch in China and the anticipated Medicare reimbursement increase for epilepsy therapy further support a positive sentiment. Although management avoided some specifics, the overall sentiment is positive, considering the strategic initiatives and growth prospects.
Key Financial Performance
Organic Revenue Growth 13% year-over-year increase, driven by momentum in the cardiopulmonary business and solid epilepsy performance across all regions.
Cardiopulmonary Segment Revenue $203 million, a 16% increase year-over-year, driven by over 20% growth in heart-lung machine revenue and mid-teens growth in cardiopulmonary consumables revenue. Reasons include sequential acceleration in Essenz placements, favorable price premiums, market share gains, and procedure growth.
Epilepsy Revenue 6% year-over-year increase, with 12% growth in Europe and Rest of World regions and 5% growth in the U.S. Reasons include strong commercial execution and initial feedback from CORE-VNS data.
Total Revenue $358 million, an 11% increase on a constant currency basis and 13% on an organic basis year-over-year. Reasons include strong performance in core segments and favorable foreign exchange impact of $5 million.
Adjusted Gross Margin 69%, down from 70% in the prior year. Reasons include unfavorable currency changes, product mix, investments in oxygenator capacity expansion, and tariff impacts, partially offset by favorable pricing.
Adjusted SG&A Expense $123 million, up from $112 million year-over-year. SG&A as a percentage of revenue decreased from 35% to 34%, driven by fixed cost leverage.
Adjusted R&D Expense $45 million, down from $47 million year-over-year. R&D as a percentage of revenue decreased from 15% to 13%, driven by cost optimization of the DTD program.
Adjusted Operating Income $80 million, up from $64 million year-over-year. Operating income margin increased from 20% to 23%, driven by higher revenue, fixed cost leverage, and DTD program optimization.
Adjusted Diluted Earnings Per Share $1.11, up from $0.90 year-over-year, driven by adjusted operating income growth.
Cash Balance $646 million as of September 30, up from $429 million at year-end 2024. Reasons include improvements in operating cash flows and release of $295 million of restricted cash.
Total Debt $434 million as of September 30, down from $628 million at year-end 2024. Reasons include $200 million early repayment of term facilities.
Adjusted Free Cash Flow $130 million for the first 9 months of 2025, up from $101 million year-over-year, driven by stronger operating results and disciplined working capital management.
Capital Spend $49 million for the first 9 months of 2025, up from $37 million year-over-year, driven by IT investments and cardiopulmonary capacity expansion initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Essenz Heart-Lung Machine: Revenue grew over 20% year-over-year, driven by sequential acceleration in placements and favorable price premiums. Commercial launch initiated in China, with positive early feedback.
Oxygenator: Strong demand continues to outpace supply. Manufacturing capacity expansion is on track, but third-party component supply remains a limiting factor.
China Market Expansion: Commercial launch of Essenz Heart-Lung Machine in China, the second-largest market after the U.S., with positive early feedback from hospitals and clinicians.
Revenue Growth: Achieved 13% organic revenue growth year-over-year, driven by cardiopulmonary and epilepsy segments.
Operational Efficiency: Expanded margins and improved cash generation. Adjusted operating income margin increased to 23% from 20% year-over-year.
Cost Optimization: Reduced R&D expenses as a percentage of revenue and optimized costs in the difficult-to-treat depression program.
Strategic Framework and Branding: Introduced a new strategic framework and refreshed logo to reflect growth and innovation focus.
Obstructive Sleep Apnea and Depression Programs: Continued progress in these programs, targeting large patient populations with unmet needs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Constraints: Strong demand for Oxygenator continues to outpace the market's ability to supply. Third-party component supply is a limiting factor for more rapid expansion, despite progress in manufacturing capacity expansion plans.
Tariff Impacts: The company estimates a tariff net impact of less than $5 million on adjusted operating income for the full year. Tariffs remain a dynamic challenge, requiring ongoing monitoring and mitigation efforts.
Currency Fluctuations: Unfavorable currency changes negatively impacted adjusted gross margin as a percent of net revenue, contributing to a year-over-year decrease.
Regulatory and Legislative Risks: The company reduced its reserve for the Italian payback measure by $3.8 million due to recent legislative developments, indicating ongoing exposure to regulatory and legislative uncertainties.
Cost Pressures: Incremental investments related to oxygenator capacity expansion and the Essenz printed circuit board conversion are expected to increase costs, impacting margins in the short term.
Market Penetration Challenges: The commercial launch of Essenz in China is in its early stages, with meaningful growth expected only in 2026, highlighting the long sales cycles and gradual market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cardiopulmonary Revenue Growth: Cardiopulmonary revenue is expected to grow 12.5% to 13.5% for the full year 2025, up from the previous guidance of 12% to 13%. This includes continued growth in Heart-Lung Machine (HLM) placements, with Essenz expected to represent approximately 60% of annual HLM unit placements in 2025, up from 40% in 2024. The forecast also reflects robust market and share growth for consumables.
Epilepsy Revenue Growth: Epilepsy revenue growth is now expected to be 5% to 6% for the full year 2025, up from the previous guidance of 4.5% to 5.5%. This includes mid-single-digit growth in the U.S. and low double-digit growth in Europe and Rest of World regions.
Overall Organic Revenue Growth: The overall organic revenue growth outlook for 2025 has been raised by 50 basis points to between 9.5% and 10.5%.
Adjusted Diluted Earnings Per Share: Adjusted diluted earnings per share for 2025 is now projected to be in the range of $3.80 to $3.90, reflecting increased revenue expectations and productivity improvements.
Adjusted Free Cash Flow: Adjusted free cash flow for 2025 is now expected to be in the range of $160 million to $180 million, which is $20 million higher than the prior guidance due to higher net income expectations, working capital improvements, and lower capital spend.
Capital Expenditures: Capital expenditures for 2025 are now expected to be approximately $80 million, down from $95 million previously, due to the cadence of capital projects.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key factors contributing to the conservative Q4 EPS guidance?
A:The Q4 EPS guidance reflects a $0.10 impact from the planned investment in printed circuit board assembly (PCBA), which is a strategic move to drive future revenue with software and services. This investment was previously foreshadowed.
Q:Can you provide more details on the oxygenator business, including internal capacity investments and third-party supply challenges?
A:The company has been expanding its manufacturing capacity, with a 10% increase last year and a 15% increase this year. However, actual output is below 10% due to third-party component supply deficits. A new manufacturing line is being added next year to further increase capacity.
Q:Why does the Q4 revenue guidance suggest a growth deceleration despite easier comps?
A:The Q4 revenue guidance is prudent, with the biggest factor being tough comps related to the HLM business, which had a strong quarter last year. Despite this, the company expects 8% growth for Q4.
Q:What are the expectations for the Essenz launch in China and its impact?
A:The Essenz launch in China began in August, six months ahead of schedule. Initial feedback has been positive, but the selling cycle for equipment is long. The majority of growth impact is expected in 2026, with China being a major contributor to the global increase in Essenz placements.
Q:What is the outlook for the neuro business, particularly in epilepsy?
A:The neuro business is stabilizing, with strong global execution and positive results from the CORE-VNS study. The study showed significant seizure reduction, and reimbursement improvements are expected to drive growth. The company will provide more details at the Investor Day.
Q:What is the status of the depression pipeline and CMS reimbursement process?
A:The CMS reimbursement process for depression is ongoing. The company has submitted a draft application and answered questions from CMS. The process was temporarily paused due to the government shutdown but is expected to take about a year once resumed.
Q:What is the contribution of the China Essenz launch in Q3, and how will it evolve?
A:The China Essenz launch contributed early orders in Q3, driven by distributor and hospital demand. Most of the impact is expected next year, with China being a major driver of the increase in Essenz placements globally.
Q:How is the company balancing top-line growth with EBITDA margin expansion?
A:The company plans to discuss its long-term strategy and financial objectives, including balancing top-line growth and EBITDA margin expansion, at the upcoming Investor Day.
Q:What are the drivers of growth in the oxygenator business, and how is the company addressing capacity constraints?
A:Growth drivers include share gains, aging population, emerging markets, and increased valve procedures. The company is addressing capacity constraints by adding a new manufacturing line next year and planning a next-generation oxygenator launch.
Q:How is the company managing the PCB upgrade and its impact on sales?
A:The PCB upgrade will be executed by the service organization, ensuring no disruption to the sales team.
Q:What is the company's approach to free cash flow and M&A capacity?
A:The company is focused on improving cash generation, which provides flexibility for strategic initiatives, including M&A, after addressing the SNIA payment.
Q:What is the commercial strategy for the epilepsy business, and what inning is the company in?
A:The epilepsy business is seeing strong execution and market penetration efforts, supported by clinical evidence, reimbursement improvements, and innovation. The company will provide more details at the Investor Day.
Q:What are the investment plans for DTD and OSA, and how will they impact growth?
A:The company will discuss its plans for DTD and OSA, including their financial impact and strategy, at the Investor Day.
Q:How does the company view the Q4 guidance and its implications for 2026?
A:The Q4 guidance reflects a balanced approach, and the company will provide 2026 guidance in February, considering various headwinds and tailwinds.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of the new manufacturing line for oxygenators, the exact capacity increase, and the step change expected. Additionally, they deferred detailed discussions on the long-term strategy for DTD and OSA, as well as the 2026 guidance, to the upcoming Investor Day.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CORE VNS
Capital month
Cardiopulmonary consumables
Cardiopulmonary segment
China HLM
DTD program
Day week
Europe World
Investor Day
World region
action
assessment
circuit
community
component
cost leverage
date
decrease
epilepsy region
expectation
feedback
foundation
framework
future
improvement cash
increase investment
launch
momentum epilepsy
month period
optimization DTD
payback
percent line
placement market
pricing
priority
productivity improvement
rollout
LIVN Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call presents a mixed outlook: strong cardiopulmonary growth and Essenz penetration are positives, but challenges in the HGNS market and uncertainties in the epilepsy business post-reimbursement change are concerning. The Middle East conflict's impact and management's vague responses add uncertainty. The overall revenue growth and adjusted income margin projections are stable, but the lack of guidance specifics and potential market risks balance the positives. Given these factors, the stock price is likely to remain neutral in the short term.
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary highlights increased guidance across multiple financial metrics, including revenue and EPS, alongside strategic growth in cardiopulmonary and epilepsy segments. The Q&A section reveals positive analyst sentiment and confidence in management's ability to execute on guidance, with no major risks identified. The company's proactive approach to reimbursement changes and product launches further supports a positive outlook. Despite conservative assumptions for 2026, the current guidance and market strategy suggest a likely positive stock price movement in the near term.
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
LIVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
